Global Hemorrhagic Septicemia Vaccines Market

Hemorrhagic Septicemia Vaccines Comprehensive Study by Type (Oil - Adjuvant, Aluminium Hydroxide- Adjuvant), Application (Cattle, Buffaloes), End User (Veterinary Hospitals, Veterinary Clinics, Animal Care Centres) Players and Region - Global Market Outlook to 2030

Hemorrhagic Septicemia Vaccines Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hemorrhagic Septicemia Vaccines
Hemorrhagic septicemia (HS), is an economically important disease of buffaloes and different cows, in southeast Asia regions of Asia, primarily in a geographical area, wherever the population of buffaloes is high. It's caused by the organism Pasteurella multocida. Vaccination for this illness is practiced worldwide in numerous geographies of the planet. Generally, hydroxide gel vaccines, alum precipitated vaccines, and/or bacterins are administered twice a year for illness prevention. This is often done double a year due to the actual fact that these vaccines provide immunity for 4 to 6 months. Many countries use OAV or oil adjuvant immunizing agent, which supplies longer length and a high degree of immunity, i.e., up to a year. By experimentation, a multiple emulsion and/or a double emulsion immunizing agent contains a skinny viscousness that has conjointly been developed by scientists that are given with OAV. At present, from a strain of deer, a live immunizing agent has been developed in Myanmar. This live immunizing agent offers immunity for over a year, however, it's its own limitations. The present review offers information regarding the immunizing agent for hemorrhagic septicemia, that has been developed using whole bacteria or parts of bacteria.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.3%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European Players will contribute the maximum growth to Global Hemorrhagic Septicemia Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bio-Labs (PVT) Limited (India), Intervac (PVT) Ltd (India), Brilliant Bio Pharma (India), Ceva Sante Animale (France), Vecol (Brazil), C.A. Laboratorios Asociados (CALA) (Italy), Institute of Animal Health and Veterinary Biologicals (India), FATRO (Italy), Institute of Veterinary Preventive Medicine (India), Indian Immunologicals Limited (India), Zoetis (United States), LABIOFAM (Vietnam) and Limor de Colombia (Spain) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Laboratorios Ovejero (Spain), National Veterinary Research Institute (India) and Laboratorios Laverlam (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hemorrhagic Septicemia Vaccines market by Type (Oil - Adjuvant and Aluminium Hydroxide- Adjuvant), Application (Cattle and Buffaloes) and Region.



On the basis of geography, the market of Hemorrhagic Septicemia Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Veterinary Hospitals will boost the Hemorrhagic Septicemia Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Trend in The Awareness of The Vaccine and Increase in The Recommendation for The Vaccine by The Veterinary Doctors

Market Growth Drivers:
Increase in Demand for Milk and Animal Protein and Rise in Expenditure on Health Care of Companion Animals

Challenges:
Fluctuating Price of Raw Materials

Restraints:
High Cost of The Vaccine

Opportunities:
Increased Research and Development for The Vaccine and Rise in Funding from The Government Organizations

Market Leaders and their expansionary development strategies
In March 2023, Vaccine maker Indian Immunologicals (IIL) announced a partnership with the Central Institute of Freshwater Aquaculture (CIFA) for commercial development of a vaccine against hemorrhagic septicemia in freshwater fish.it had announced commercial development of fish vaccines with the Central Institute of Fisheries Education (CIFE).
In August 2023, Indian Immunologicals Ltd (IIL), a vaccine manufacturer, has announced a partnership with Central Institute of Freshwater Aquaculture (CIFA), Bhubaneswar, an Indian Council of Agricultural Research (ICAR) Institute, for commercial development of vaccine against Hemorrhagic Septicemia, also called Aeromonas Septicemia, ulcer disease or red-sore disease in freshwater fish.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Hemorrhagic Septicemia Vaccines, Suppliers and Distributors of Hemorrhagic Septicemia Vaccines, Venture Capitalists and Private Equity Firms and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Oil - Adjuvant
  • Aluminium Hydroxide- Adjuvant
By Application
  • Cattle
  • Buffaloes
By End User
  • Veterinary Hospitals
  • Veterinary Clinics
  • Animal Care Centres

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Demand for Milk and Animal Protein
      • 3.2.2. Rise in Expenditure on Health Care of Companion Animals
    • 3.3. Market Challenges
      • 3.3.1. Fluctuating Price of Raw Materials
    • 3.4. Market Trends
      • 3.4.1. Increasing Trend in The Awareness of The Vaccine
      • 3.4.2. Increase in The Recommendation for The Vaccine by The Veterinary Doctors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemorrhagic Septicemia Vaccines, by Type, Application, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemorrhagic Septicemia Vaccines (Value)
      • 5.2.1. Global Hemorrhagic Septicemia Vaccines by: Type (Value)
        • 5.2.1.1. Oil - Adjuvant
        • 5.2.1.2. Aluminium Hydroxide- Adjuvant
      • 5.2.2. Global Hemorrhagic Septicemia Vaccines by: Application (Value)
        • 5.2.2.1. Cattle
        • 5.2.2.2. Buffaloes
      • 5.2.3. Global Hemorrhagic Septicemia Vaccines by: End User (Value)
        • 5.2.3.1. Veterinary Hospitals
        • 5.2.3.2. Veterinary Clinics
        • 5.2.3.3. Animal Care Centres
      • 5.2.4. Global Hemorrhagic Septicemia Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Hemorrhagic Septicemia Vaccines (Volume)
      • 5.3.1. Global Hemorrhagic Septicemia Vaccines by: Type (Volume)
        • 5.3.1.1. Oil - Adjuvant
        • 5.3.1.2. Aluminium Hydroxide- Adjuvant
      • 5.3.2. Global Hemorrhagic Septicemia Vaccines by: Application (Volume)
        • 5.3.2.1. Cattle
        • 5.3.2.2. Buffaloes
      • 5.3.3. Global Hemorrhagic Septicemia Vaccines by: End User (Volume)
        • 5.3.3.1. Veterinary Hospitals
        • 5.3.3.2. Veterinary Clinics
        • 5.3.3.3. Animal Care Centres
      • 5.3.4. Global Hemorrhagic Septicemia Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Hemorrhagic Septicemia Vaccines (Price)
      • 5.4.1. Global Hemorrhagic Septicemia Vaccines by: Type (Price)
  • 6. Hemorrhagic Septicemia Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bio-Labs (PVT) Limited (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Intervac (PVT) Ltd (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Brilliant Bio Pharma (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ceva Sante Animale (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vecol (Brazil)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. C.A. Laboratorios Asociados (CALA) (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Institute of Animal Health and Veterinary Biologicals (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. FATRO (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Institute of Veterinary Preventive Medicine (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Indian Immunologicals Limited (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Zoetis (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. LABIOFAM (Vietnam)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Limor de Colombia (Spain)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Hemorrhagic Septicemia Vaccines Sale, by Type, Application, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemorrhagic Septicemia Vaccines (Value)
      • 7.2.1. Global Hemorrhagic Septicemia Vaccines by: Type (Value)
        • 7.2.1.1. Oil - Adjuvant
        • 7.2.1.2. Aluminium Hydroxide- Adjuvant
      • 7.2.2. Global Hemorrhagic Septicemia Vaccines by: Application (Value)
        • 7.2.2.1. Cattle
        • 7.2.2.2. Buffaloes
      • 7.2.3. Global Hemorrhagic Septicemia Vaccines by: End User (Value)
        • 7.2.3.1. Veterinary Hospitals
        • 7.2.3.2. Veterinary Clinics
        • 7.2.3.3. Animal Care Centres
      • 7.2.4. Global Hemorrhagic Septicemia Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Hemorrhagic Septicemia Vaccines (Volume)
      • 7.3.1. Global Hemorrhagic Septicemia Vaccines by: Type (Volume)
        • 7.3.1.1. Oil - Adjuvant
        • 7.3.1.2. Aluminium Hydroxide- Adjuvant
      • 7.3.2. Global Hemorrhagic Septicemia Vaccines by: Application (Volume)
        • 7.3.2.1. Cattle
        • 7.3.2.2. Buffaloes
      • 7.3.3. Global Hemorrhagic Septicemia Vaccines by: End User (Volume)
        • 7.3.3.1. Veterinary Hospitals
        • 7.3.3.2. Veterinary Clinics
        • 7.3.3.3. Animal Care Centres
      • 7.3.4. Global Hemorrhagic Septicemia Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Hemorrhagic Septicemia Vaccines (Price)
      • 7.4.1. Global Hemorrhagic Septicemia Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemorrhagic Septicemia Vaccines: by Type(USD Million)
  • Table 2. Hemorrhagic Septicemia Vaccines Oil - Adjuvant , by Region USD Million (2018-2023)
  • Table 3. Hemorrhagic Septicemia Vaccines Aluminium Hydroxide- Adjuvant , by Region USD Million (2018-2023)
  • Table 4. Hemorrhagic Septicemia Vaccines: by Application(USD Million)
  • Table 5. Hemorrhagic Septicemia Vaccines Cattle , by Region USD Million (2018-2023)
  • Table 6. Hemorrhagic Septicemia Vaccines Buffaloes , by Region USD Million (2018-2023)
  • Table 7. Hemorrhagic Septicemia Vaccines: by End User(USD Million)
  • Table 8. Hemorrhagic Septicemia Vaccines Veterinary Hospitals , by Region USD Million (2018-2023)
  • Table 9. Hemorrhagic Septicemia Vaccines Veterinary Clinics , by Region USD Million (2018-2023)
  • Table 10. Hemorrhagic Septicemia Vaccines Animal Care Centres , by Region USD Million (2018-2023)
  • Table 11. South America Hemorrhagic Septicemia Vaccines, by Country USD Million (2018-2023)
  • Table 12. South America Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 13. South America Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 14. South America Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 15. Brazil Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 16. Brazil Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 17. Brazil Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 18. Argentina Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 19. Argentina Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 20. Argentina Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 21. Rest of South America Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 24. Asia Pacific Hemorrhagic Septicemia Vaccines, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 28. China Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 29. China Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 30. China Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 31. Japan Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 32. Japan Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 33. Japan Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 34. India Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 35. India Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 36. India Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 37. South Korea Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 38. South Korea Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 39. South Korea Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 40. Taiwan Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 41. Taiwan Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 42. Taiwan Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 43. Australia Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 44. Australia Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 45. Australia Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 49. Europe Hemorrhagic Septicemia Vaccines, by Country USD Million (2018-2023)
  • Table 50. Europe Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 51. Europe Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 52. Europe Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 53. Germany Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 54. Germany Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 55. Germany Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 56. France Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 57. France Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 58. France Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 59. Italy Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 60. Italy Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 61. Italy Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 62. United Kingdom Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 65. Netherlands Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 66. Netherlands Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 67. Netherlands Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 68. Rest of Europe Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 71. MEA Hemorrhagic Septicemia Vaccines, by Country USD Million (2018-2023)
  • Table 72. MEA Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 73. MEA Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 74. MEA Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 75. Middle East Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 76. Middle East Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 77. Middle East Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 78. Africa Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 79. Africa Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 80. Africa Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 81. North America Hemorrhagic Septicemia Vaccines, by Country USD Million (2018-2023)
  • Table 82. North America Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 83. North America Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 84. North America Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 85. United States Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 86. United States Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 87. United States Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 88. Canada Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 89. Canada Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 90. Canada Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 91. Mexico Hemorrhagic Septicemia Vaccines, by Type USD Million (2018-2023)
  • Table 92. Mexico Hemorrhagic Septicemia Vaccines, by Application USD Million (2018-2023)
  • Table 93. Mexico Hemorrhagic Septicemia Vaccines, by End User USD Million (2018-2023)
  • Table 94. Hemorrhagic Septicemia Vaccines Sales: by Type(K Units)
  • Table 95. Hemorrhagic Septicemia Vaccines Sales Oil - Adjuvant , by Region K Units (2018-2023)
  • Table 96. Hemorrhagic Septicemia Vaccines Sales Aluminium Hydroxide- Adjuvant , by Region K Units (2018-2023)
  • Table 97. Hemorrhagic Septicemia Vaccines Sales: by Application(K Units)
  • Table 98. Hemorrhagic Septicemia Vaccines Sales Cattle , by Region K Units (2018-2023)
  • Table 99. Hemorrhagic Septicemia Vaccines Sales Buffaloes , by Region K Units (2018-2023)
  • Table 100. Hemorrhagic Septicemia Vaccines Sales: by End User(K Units)
  • Table 101. Hemorrhagic Septicemia Vaccines Sales Veterinary Hospitals , by Region K Units (2018-2023)
  • Table 102. Hemorrhagic Septicemia Vaccines Sales Veterinary Clinics , by Region K Units (2018-2023)
  • Table 103. Hemorrhagic Septicemia Vaccines Sales Animal Care Centres , by Region K Units (2018-2023)
  • Table 104. South America Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2018-2023)
  • Table 105. South America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 106. South America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 107. South America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 108. Brazil Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 109. Brazil Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 110. Brazil Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 111. Argentina Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 112. Argentina Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 113. Argentina Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 114. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 115. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 116. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 117. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2018-2023)
  • Table 118. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 119. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 120. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 121. China Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 122. China Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 123. China Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 124. Japan Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 125. Japan Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 126. Japan Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 127. India Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 128. India Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 129. India Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 130. South Korea Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 131. South Korea Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 132. South Korea Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 133. Taiwan Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 134. Taiwan Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 135. Taiwan Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 136. Australia Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 137. Australia Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 138. Australia Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 139. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 140. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 141. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 142. Europe Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2018-2023)
  • Table 143. Europe Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 144. Europe Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 145. Europe Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 146. Germany Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 147. Germany Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 148. Germany Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 149. France Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 150. France Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 151. France Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 152. Italy Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 153. Italy Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 154. Italy Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 155. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 156. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 157. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 158. Netherlands Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 159. Netherlands Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 160. Netherlands Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 161. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 162. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 163. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 164. MEA Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2018-2023)
  • Table 165. MEA Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 166. MEA Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 167. MEA Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 168. Middle East Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 169. Middle East Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 170. Middle East Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 171. Africa Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 172. Africa Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 173. Africa Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 174. North America Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2018-2023)
  • Table 175. North America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 176. North America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 177. North America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 178. United States Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 179. United States Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 180. United States Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 181. Canada Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 182. Canada Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 183. Canada Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 184. Mexico Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2018-2023)
  • Table 185. Mexico Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2018-2023)
  • Table 186. Mexico Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2018-2023)
  • Table 187. Hemorrhagic Septicemia Vaccines: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Hemorrhagic Septicemia Vaccines: by Type(USD Million)
  • Table 202. Hemorrhagic Septicemia Vaccines Oil - Adjuvant , by Region USD Million (2025-2030)
  • Table 203. Hemorrhagic Septicemia Vaccines Aluminium Hydroxide- Adjuvant , by Region USD Million (2025-2030)
  • Table 204. Hemorrhagic Septicemia Vaccines: by Application(USD Million)
  • Table 205. Hemorrhagic Septicemia Vaccines Cattle , by Region USD Million (2025-2030)
  • Table 206. Hemorrhagic Septicemia Vaccines Buffaloes , by Region USD Million (2025-2030)
  • Table 207. Hemorrhagic Septicemia Vaccines: by End User(USD Million)
  • Table 208. Hemorrhagic Septicemia Vaccines Veterinary Hospitals , by Region USD Million (2025-2030)
  • Table 209. Hemorrhagic Septicemia Vaccines Veterinary Clinics , by Region USD Million (2025-2030)
  • Table 210. Hemorrhagic Septicemia Vaccines Animal Care Centres , by Region USD Million (2025-2030)
  • Table 211. South America Hemorrhagic Septicemia Vaccines, by Country USD Million (2025-2030)
  • Table 212. South America Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 213. South America Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 214. South America Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 215. Brazil Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 216. Brazil Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 217. Brazil Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 218. Argentina Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 219. Argentina Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 220. Argentina Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 221. Rest of South America Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 222. Rest of South America Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 223. Rest of South America Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 224. Asia Pacific Hemorrhagic Septicemia Vaccines, by Country USD Million (2025-2030)
  • Table 225. Asia Pacific Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 226. Asia Pacific Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 227. Asia Pacific Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 228. China Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 229. China Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 230. China Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 231. Japan Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 232. Japan Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 233. Japan Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 234. India Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 235. India Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 236. India Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 237. South Korea Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 238. South Korea Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 239. South Korea Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 240. Taiwan Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 241. Taiwan Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 242. Taiwan Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 243. Australia Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 244. Australia Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 245. Australia Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 249. Europe Hemorrhagic Septicemia Vaccines, by Country USD Million (2025-2030)
  • Table 250. Europe Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 251. Europe Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 252. Europe Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 253. Germany Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 254. Germany Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 255. Germany Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 256. France Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 257. France Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 258. France Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 259. Italy Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 260. Italy Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 261. Italy Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 262. United Kingdom Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 263. United Kingdom Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 264. United Kingdom Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 265. Netherlands Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 266. Netherlands Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 267. Netherlands Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 268. Rest of Europe Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 269. Rest of Europe Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 270. Rest of Europe Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 271. MEA Hemorrhagic Septicemia Vaccines, by Country USD Million (2025-2030)
  • Table 272. MEA Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 273. MEA Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 274. MEA Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 275. Middle East Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 276. Middle East Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 277. Middle East Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 278. Africa Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 279. Africa Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 280. Africa Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 281. North America Hemorrhagic Septicemia Vaccines, by Country USD Million (2025-2030)
  • Table 282. North America Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 283. North America Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 284. North America Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 285. United States Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 286. United States Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 287. United States Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 288. Canada Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 289. Canada Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 290. Canada Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 291. Mexico Hemorrhagic Septicemia Vaccines, by Type USD Million (2025-2030)
  • Table 292. Mexico Hemorrhagic Septicemia Vaccines, by Application USD Million (2025-2030)
  • Table 293. Mexico Hemorrhagic Septicemia Vaccines, by End User USD Million (2025-2030)
  • Table 294. Hemorrhagic Septicemia Vaccines Sales: by Type(K Units)
  • Table 295. Hemorrhagic Septicemia Vaccines Sales Oil - Adjuvant , by Region K Units (2025-2030)
  • Table 296. Hemorrhagic Septicemia Vaccines Sales Aluminium Hydroxide- Adjuvant , by Region K Units (2025-2030)
  • Table 297. Hemorrhagic Septicemia Vaccines Sales: by Application(K Units)
  • Table 298. Hemorrhagic Septicemia Vaccines Sales Cattle , by Region K Units (2025-2030)
  • Table 299. Hemorrhagic Septicemia Vaccines Sales Buffaloes , by Region K Units (2025-2030)
  • Table 300. Hemorrhagic Septicemia Vaccines Sales: by End User(K Units)
  • Table 301. Hemorrhagic Septicemia Vaccines Sales Veterinary Hospitals , by Region K Units (2025-2030)
  • Table 302. Hemorrhagic Septicemia Vaccines Sales Veterinary Clinics , by Region K Units (2025-2030)
  • Table 303. Hemorrhagic Septicemia Vaccines Sales Animal Care Centres , by Region K Units (2025-2030)
  • Table 304. South America Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2025-2030)
  • Table 305. South America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 306. South America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 307. South America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 308. Brazil Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 309. Brazil Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 310. Brazil Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 311. Argentina Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 312. Argentina Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 313. Argentina Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 314. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 315. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 316. Rest of South America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 317. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2025-2030)
  • Table 318. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 319. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 320. Asia Pacific Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 321. China Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 322. China Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 323. China Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 324. Japan Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 325. Japan Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 326. Japan Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 327. India Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 328. India Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 329. India Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 330. South Korea Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 331. South Korea Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 332. South Korea Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 333. Taiwan Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 334. Taiwan Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 335. Taiwan Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 336. Australia Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 337. Australia Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 338. Australia Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 339. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 340. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 341. Rest of Asia-Pacific Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 342. Europe Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2025-2030)
  • Table 343. Europe Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 344. Europe Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 345. Europe Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 346. Germany Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 347. Germany Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 348. Germany Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 349. France Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 350. France Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 351. France Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 352. Italy Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 353. Italy Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 354. Italy Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 355. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 356. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 357. United Kingdom Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 358. Netherlands Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 359. Netherlands Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 360. Netherlands Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 361. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 362. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 363. Rest of Europe Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 364. MEA Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2025-2030)
  • Table 365. MEA Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 366. MEA Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 367. MEA Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 368. Middle East Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 369. Middle East Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 370. Middle East Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 371. Africa Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 372. Africa Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 373. Africa Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 374. North America Hemorrhagic Septicemia Vaccines Sales, by Country K Units (2025-2030)
  • Table 375. North America Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 376. North America Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 377. North America Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 378. United States Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 379. United States Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 380. United States Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 381. Canada Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 382. Canada Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 383. Canada Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 384. Mexico Hemorrhagic Septicemia Vaccines Sales, by Type K Units (2025-2030)
  • Table 385. Mexico Hemorrhagic Septicemia Vaccines Sales, by Application K Units (2025-2030)
  • Table 386. Mexico Hemorrhagic Septicemia Vaccines Sales, by End User K Units (2025-2030)
  • Table 387. Hemorrhagic Septicemia Vaccines: by Type(USD/Units)
  • Table 388. Research Programs/Design for This Report
  • Table 389. Key Data Information from Secondary Sources
  • Table 390. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemorrhagic Septicemia Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Hemorrhagic Septicemia Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Hemorrhagic Septicemia Vaccines: by End User USD Million (2018-2023)
  • Figure 7. South America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 9. Europe Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 10. MEA Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 11. North America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 12. Global Hemorrhagic Septicemia Vaccines: by Type K Units (2018-2023)
  • Figure 13. Global Hemorrhagic Septicemia Vaccines: by Application K Units (2018-2023)
  • Figure 14. Global Hemorrhagic Septicemia Vaccines: by End User K Units (2018-2023)
  • Figure 15. South America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 17. Europe Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 18. MEA Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 19. North America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 20. Global Hemorrhagic Septicemia Vaccines: by Type USD/Units (2018-2023)
  • Figure 21. Global Hemorrhagic Septicemia Vaccines share by Players 2023 (%)
  • Figure 22. Global Hemorrhagic Septicemia Vaccines share by Players (Top 3) 2023(%)
  • Figure 23. Global Hemorrhagic Septicemia Vaccines share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Bio-Labs (PVT) Limited (India) Revenue, Net Income and Gross profit
  • Figure 26. Bio-Labs (PVT) Limited (India) Revenue: by Geography 2023
  • Figure 27. Intervac (PVT) Ltd (India) Revenue, Net Income and Gross profit
  • Figure 28. Intervac (PVT) Ltd (India) Revenue: by Geography 2023
  • Figure 29. Brilliant Bio Pharma (India) Revenue, Net Income and Gross profit
  • Figure 30. Brilliant Bio Pharma (India) Revenue: by Geography 2023
  • Figure 31. Ceva Sante Animale (France) Revenue, Net Income and Gross profit
  • Figure 32. Ceva Sante Animale (France) Revenue: by Geography 2023
  • Figure 33. Vecol (Brazil) Revenue, Net Income and Gross profit
  • Figure 34. Vecol (Brazil) Revenue: by Geography 2023
  • Figure 35. C.A. Laboratorios Asociados (CALA) (Italy) Revenue, Net Income and Gross profit
  • Figure 36. C.A. Laboratorios Asociados (CALA) (Italy) Revenue: by Geography 2023
  • Figure 37. Institute of Animal Health and Veterinary Biologicals (India) Revenue, Net Income and Gross profit
  • Figure 38. Institute of Animal Health and Veterinary Biologicals (India) Revenue: by Geography 2023
  • Figure 39. FATRO (Italy) Revenue, Net Income and Gross profit
  • Figure 40. FATRO (Italy) Revenue: by Geography 2023
  • Figure 41. Institute of Veterinary Preventive Medicine (India) Revenue, Net Income and Gross profit
  • Figure 42. Institute of Veterinary Preventive Medicine (India) Revenue: by Geography 2023
  • Figure 43. Indian Immunologicals Limited (India) Revenue, Net Income and Gross profit
  • Figure 44. Indian Immunologicals Limited (India) Revenue: by Geography 2023
  • Figure 45. Zoetis (United States) Revenue, Net Income and Gross profit
  • Figure 46. Zoetis (United States) Revenue: by Geography 2023
  • Figure 47. LABIOFAM (Vietnam) Revenue, Net Income and Gross profit
  • Figure 48. LABIOFAM (Vietnam) Revenue: by Geography 2023
  • Figure 49. Limor de Colombia (Spain) Revenue, Net Income and Gross profit
  • Figure 50. Limor de Colombia (Spain) Revenue: by Geography 2023
  • Figure 51. Global Hemorrhagic Septicemia Vaccines: by Type USD Million (2025-2030)
  • Figure 52. Global Hemorrhagic Septicemia Vaccines: by Application USD Million (2025-2030)
  • Figure 53. Global Hemorrhagic Septicemia Vaccines: by End User USD Million (2025-2030)
  • Figure 54. South America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 55. Asia Pacific Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 56. Europe Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 57. MEA Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 58. North America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 59. Global Hemorrhagic Septicemia Vaccines: by Type K Units (2025-2030)
  • Figure 60. Global Hemorrhagic Septicemia Vaccines: by Application K Units (2025-2030)
  • Figure 61. Global Hemorrhagic Septicemia Vaccines: by End User K Units (2025-2030)
  • Figure 62. South America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 63. Asia Pacific Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 64. Europe Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 65. MEA Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 66. North America Hemorrhagic Septicemia Vaccines Share (%), by Country
  • Figure 67. Global Hemorrhagic Septicemia Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bio-Labs (PVT) Limited (India)
  • Intervac (PVT) Ltd (India)
  • Brilliant Bio Pharma (India)
  • Ceva Sante Animale (France)
  • Vecol (Brazil)
  • C.A. Laboratorios Asociados (CALA) (Italy)
  • Institute of Animal Health and Veterinary Biologicals (India)
  • FATRO (Italy)
  • Institute of Veterinary Preventive Medicine (India)
  • Indian Immunologicals Limited (India)
  • Zoetis (United States)
  • LABIOFAM (Vietnam)
  • Limor de Colombia (Spain)
Additional players considered in the study are as follows:
Laboratorios Ovejero (Spain) , National Veterinary Research Institute (India) , Laboratorios Laverlam (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 243 Pages 50 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemorrhagic Septicemia Vaccines Market Quantitative research analysis
Global Hemorrhagic Septicemia Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bio-Labs (PVT) Limited (India), Intervac (PVT) Ltd (India), Brilliant Bio Pharma (India), Ceva Sante Animale (France), Vecol (Brazil), C.A. Laboratorios Asociados (CALA) (Italy), Institute of Animal Health and Veterinary Biologicals (India), FATRO (Italy), Institute of Veterinary Preventive Medicine (India), Indian Immunologicals Limited (India), Zoetis (United States), LABIOFAM (Vietnam) and Limor de Colombia (Spain) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Trend in The Awareness of The Vaccine " is seen as one of major influencing trends for Hemorrhagic Septicemia Vaccines Market during projected period 2023-2030.
The Hemorrhagic Septicemia Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hemorrhagic Septicemia Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Immunosuppressant Drugs Comprehensive Study by End-users (Hospitals, Clinics, Others), Indication (Organ Transplantation, Autoimmune Disorders, Non-autoimmune Inflammatory Diseases), Distribution Cha...
$ 3750
Rupatadine Comprehensive Study by Type (150 mg Tablets, 300 mg Tablets, Others), Application (Allergic Rhinitis, Urticaria), Dosage (Tablets, Capsules, Syrup), End User (Hospitals, Clinics) Players a...
$ 3500
Pharma Ophthalmic Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Independent Pharmacies & Drug Stores), Therap...
$ 3750
Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Cli...
$ 3350
Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
$ 3650
Myocardial Infarction Drugs Comprehensive Study by Type (Vasodilators {Nitrodilators, ACE Inhibitors, ARBs}, Cardiac depressant drugs {Beta Blockers}, Antiarrhythmics {Anti-thrombotics}, Thrombolytic...
$ 3650